Page C Moore
Overview
Explore the profile of Page C Moore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harrold L, Bingham C, Pope J, OBrien J, Moore P, Roberts-Toler C, et al.
Clin Rheumatol
. 2024 Dec;
44(2):635-648.
PMID: 39707042
Objectives: To compare effectiveness of tofacitinib versus tumor necrosis factor inhibitors (TNFi), and across tofacitinib lines of therapy, in patients with rheumatoid arthritis (RA), using US CorEvitas RA Registry data....
2.
Wolf D, Naegeli A, Moore P, Janak J, Crabtree M, Shan M, et al.
Gastro Hep Adv
. 2024 Aug;
2(6):799-809.
PMID: 39130112
Background And Aims: Fecal urgency is a common symptom of Ulcerative Colitis (UC). We explored the association between changes in fecal urgency for patient characteristics and evaluated the association between...
3.
Janak J, Loughlin A, Moore P, Lemay C, Mease P, Lebwohl M, et al.
Dig Dis Sci
. 2024 May;
69(8):2784-2795.
PMID: 38811505
Background: Comparisons among autoimmune diseases enable understanding of the burden and factors associated with work productivity loss and impairment. Aims: The objective was to compare work productivity and activity and...
4.
Baker J, Bakewell C, Dikranian A, Lam G, OBrien J, Moore P, et al.
Rheumatol Ther
. 2024 Mar;
11(3):841-853.
PMID: 38507187
Introduction: Real-world studies describing biosimilar initiation or switching in patients with rheumatoid arthritis (RA) are limited. The aim of this study was to assess treatment patterns and effectiveness of real-world...
5.
Curtis J, McLean R, Lee I, Mackey R, Moore P, Haubrich R, et al.
ACR Open Rheumatol
. 2024 Mar;
6(5):253-264.
PMID: 38429905
Objective: To describe and identify associated factors for patient-clinician discordance of disease assessment at biologic or Janus kinase inhibitor (JAKi) initiation and over 12 months following initiation in patients with...
6.
Pappas D, OBrien J, Moore P, Dodge R, Germino R, Masri K, et al.
J Rheumatol
. 2024 Feb;
51(5):452-461.
PMID: 38359941
Objective: This real-world analysis assessed baseline demographics/characteristics and treatment patterns/effectiveness in patients with rheumatoid arthritis (RA) initiating tofacitinib (TOF) in the US CorEvitas RA Registry. Methods: The primary analysis of...
7.
Harrold L, Wittstock K, Kelly S, Han X, Zhuo J, Schrader A, et al.
Adv Rheumatol
. 2024 Jan;
64(1):10.
PMID: 38243281
Background: The HLA-DRB1 shared epitope (SE) is a risk factor for the development of rheumatoid arthritis (RA) and the production of anti-citrullinated protein antibodies (ACPAs) in RA patients. Our objective...
8.
Rubinstein P, Moore P, Bimali M, Lee J, Rudek M, Chadburn A, et al.
Lancet Haematol
. 2023 Aug;
10(8):e624-e632.
PMID: 37532416
Background: Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is approved in the upfront setting for advanced stage classical Hodgkin lymphoma (cHL). People living with HIV have been...
9.
Cross R, Naegeli A, Harrison R, Moore P, Mackey R, Crabtree M, et al.
Crohns Colitis 360
. 2023 Feb;
4(3):otac007.
PMID: 36777423
Background: To evaluate disease burden and patient-reported outcomes (PROs) of ulcerative colitis (UC) patients at enrollment into CorEvitas' Inflammatory Bowel Disease Registry by therapy class. Methods: Between May 3, 2017...
10.
Harrold L, Wittstock K, Kelly S, Han X, Shan Y, Guo L, et al.
Rheumatol Ther
. 2023 Feb;
10(3):575-587.
PMID: 36749478
Introduction: Currently there is limited data to drive clinical decision making regarding the choice of biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARD); thus, head-to-head comparisons are needed to help guide prescribing. ...